Table 1 DLBCL patient characteristics

From: Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma

Characteristic

Patients achieving EFS24 (N=38)

Failure to achieve EFS24 (N=13)

P-value

Diagnosis age, median (range), years; IQR

62 (26–82); 55–70

67 (57–82); 62–74

 

Age > 60 years

20 (52%)

11 (85%)

0.042

Male

25 (66%)

7 (54%)

0.44

PS 2+

5 (13%)

2 (15%)

0.84

Ann Arbor Stage III-IV

26 (68%)

9 (69%)

0.96

2+ Extranodal sites group

4 (11%)

3 (23%)

0.26

LDH >ULN

24 (63%)

10 (83%)

0.19

IPI

 0–1

11 (29%)

2 (15%)

0.35

 2

13 (34%)

3 (23%)

 

 3

11 (29%)

5 (38%)

 

 4 or 5

3 (8%)

3 (23%)

 

B Symptoms

12 (32%)

4 (31%)

0.96

Bulky disease

6 (16%)

3 (23%)

0.55

Follow-up a

 Death

2 (5%)

10 (77%)

NA

 Event

6 (16%)

13 (100%)

NA

COO (n=50)

 GCB

18 (49%)

8 (61%)

0.42

MYC-double hit (n=45)

4 (11%)

2 (20%)

0.53

  1. Treatment: R-CHOP n=43, R-EPOCH n=5, ER-CHOP n=2, R-ProMACE CytaBOM n=1.
  2. Abbreviations: COO, cell of origin; DLBCL, diffuse large B-cell lymphoma; EFS24, event-free survival at 24 months after diagnosis; GCB, germinal center B-cell; IPI, international prognostic index; IQR, interquartile range; LDH, lactate dehydrogenase; NA, not applicable; PS, performance status; ULN, upper limit of normal.
  3. aFU Months Alive Cases, median (range); IQR: 48 (29–97); (38–59).
Back to article page